SCHEMBL525056

SCHEMBL525056

CC(C)COC(=O)CCC=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.48
MAPT P10636 1/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EPHX2 P34913 1/20 0.37
DGKA P23743 1/20 0.37
LMNA P02545 2/20 0.36
CYP3A4 P08684 1/20 0.36
ATM Q13315 1/20 0.36
KDM4E B2RXH2 1/20 0.35
DUSP3 P51452 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PRKCE Q02156 1/20 0.35
PRKCQ Q04759 1/20 0.35
PRKCD Q05655 1/20 0.35
PRKCA P17252 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334176 0.85 TSHR (0.50) TSHRMAPTPOLBGAAALDH1A1
SCHEMBL7532164 0.85 MAPT (0.50) TSHRMAPTALDH1A1TDP1EPHX2
SCHEMBL8167955 0.84 MAPT (0.53) MAPTALDH1A1EPHX2DGKALMNA
SCHEMBL30529014 0.83 TSHR (0.48) TSHRMAPTPOLBGAAALDH1A1
SCHEMBL27561555 0.83 TSHR (0.48) TSHRMAPTPOLBGAAALDH1A1
SCHEMBL10401223 0.83 TSHR (0.55) TSHRMAPTPOLBGAAALDH1A1
SCHEMBL846984 0.82 EGLN1 (0.45) TSHRMAPTPOLBGAAALDH1A1
SCHEMBL3968791 0.82 TSHR (0.48) TSHRMAPTPOLBGAAALDH1A1
SCHEMBL42941 0.81 MAPT (0.59) TSHRMAPTALDH1A1TDP1EPHX2
SCHEMBL356035 0.81 MAPT (0.53) TSHRMAPTPOLBGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103052638-B Prepare the method for dimiracetam NEUROTUNE AG (CH) 2015-09-30 CN disclosed
EP-2598504-B1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2014-04-16 EP disclosed
EP-2598504-B1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2014-04-16 EP disclosed
US-8476453-B2 Process for the preparation of dimiracetam NEUROTUNE AG (CH) 2013-07-02 US disclosed
US-8476453-B2 Process for the preparation of dimiracetam NEUROTUNE AG (CH) 2013-07-02 US disclosed
US-8476453-B2 Process for the preparation of dimiracetam NEUROTUNE AG (CH) 2013-07-02 US disclosed
EP-2598504-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM Neurotune AG (CH) 2013-06-05 EP disclosed
US-20130123509-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2013-05-16 US disclosed
US-20130123509-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2013-05-16 US disclosed
US-20130123509-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2013-05-16 US disclosed
CN-103052638-A Process for the preparation of dimiracetam NEUROTUNE AG 2013-04-17 CN disclosed
WO-2012013640-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2012-02-02 WO disclosed
WO-2012013640-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM NEUROTUNE AG (CH) 2012-02-02 WO disclosed
US-5200406-A Nootropic agents; learning enhancement I.S.F. SOCIETA PER AZIONI (IT) 1993-04-06 US disclosed
US-5130319-A Cognition activators for memory disorders I.S.F. SOCIETA PER AZIONI (IT) 1992-07-14 US disclosed
US-5053422-A Learning-memory enhancers; nootropic agents I.S.F. SOCIETA PER AZIONI (IT) 1991-10-01 US disclosed
CN-1036204-A some compounds ISF SPA (IT) 1989-10-11 CN disclosed
EP-0335483-A2 Condensed imidazole derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them. ISF SOCIETA PER AZIONI (IT) 1989-10-04 EP disclosed
EP-0208272-A2 Method for the preparation of alkyl esters of 3,4-epoxybutyric acid TECNOPART S.r.l. (IT) 1987-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123509-A1 PROCESS FOR THE PREPARATION OF DIMIRACETAM ADH1A, ADH1C, OGDH TSHR 3699/4885MAPT 729/4885POLB 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.